Document Detail

Resolution of left ventricular thrombus by rivaroxaban.
MedLine Citation:
PMID:  24976470     Owner:  NLM     Status:  In-Data-Review    
Intracardiac thrombus is a potentially life-threatening condition, with a high risk of embolic complications. Although vitamin K antagonists have been traditionally used for the treatment of intracardiac thrombus, they have relevant disadvantages that limit their use. Rivaroxaban is a once daily oral anticoagulant, currently indicated for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the prevention and treatment of venous thromboembolism. We present the case of a 78-year-old man with nonvalvular atrial fibrillation, heart failure and creatinine clearance of 40 ml/min, anticoagulated with rivaroxaban 15 mg/day as the patient had very difficult access to hematologic controls. The transthoracic echocardiogram showed dilated left ventricle, severe left ventricular dysfunction and two images of thrombus, which disappeared after 4 weeks of treatment with rivaroxaban. To our knowledge, this is the first case reported regarding the resolution of left ventricular thrombosis with rivaroxaban.
Miriam Padilla Pérez; Daniel Salas Bravo; Juan Arsenio Garcelán Trigo; Eduardo Vazquez Ruiz de Castroviejo; Javier Torres Llergo; Cristóbal Lozano Cabezas; Juan Carlos Fernández Guerrero
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Future cardiology     Volume:  10     ISSN:  1744-8298     ISO Abbreviation:  Future Cardiol     Publication Date:  2014 May 
Date Detail:
Created Date:  2014-06-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101239345     Medline TA:  Future Cardiol     Country:  England    
Other Details:
Languages:  eng     Pagination:  333-6     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comparing 14-day adhesive patch with 24-h Holter monitoring.
Next Document:  Acute coronary syndrome and ethnicity: observations from the Middle East.